Knight Therapeutics Inc
TSX:GUD
Intrinsic Value
The intrinsic value of one GUD stock under the Base Case scenario is 5.79 CAD. Compared to the current market price of 5.59 CAD, Knight Therapeutics Inc is Undervalued by 3%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Knight Therapeutics Inc
Fundamental Analysis

Revenue & Expenses Breakdown
Knight Therapeutics Inc
Balance Sheet Decomposition
Knight Therapeutics Inc
Current Assets | 396.8m |
Cash & Short-Term Investments | 163.1m |
Receivables | 123.2m |
Other Current Assets | 110.4m |
Non-Current Assets | 567m |
Long-Term Investments | 92m |
PP&E | 20m |
Intangibles | 370.1m |
Other Non-Current Assets | 84.8m |
Free Cash Flow Analysis
Knight Therapeutics Inc
CAD | |
Free Cash Flow | CAD |
Earnings Waterfall
Knight Therapeutics Inc
Revenue
|
371.3m
CAD
|
Cost of Revenue
|
-196.9m
CAD
|
Gross Profit
|
174.4m
CAD
|
Operating Expenses
|
-167m
CAD
|
Operating Income
|
7.4m
CAD
|
Other Expenses
|
-3.1m
CAD
|
Net Income
|
4.3m
CAD
|
GUD Profitability Score
Profitability Due Diligence
Knight Therapeutics Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
Knight Therapeutics Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
GUD Solvency Score
Solvency Due Diligence
Knight Therapeutics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Knight Therapeutics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GUD Price Targets Summary
Knight Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for GUD is 7.71 CAD with a low forecast of 6.51 CAD and a high forecast of 9.45 CAD.
Dividends
Current shareholder yield for GUD is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one GUD stock under the Base Case scenario is 5.79 CAD.
Compared to the current market price of 5.59 CAD, Knight Therapeutics Inc is Undervalued by 3%.